Skip to main content

Table 1 Demographics and clinical characteristics of participants

From: Artificial intelligence for the diagnosis of clinically significant prostate cancer based on multimodal data: a multicenter study

Parameter

Training cohort

Validation cohort

Changhai prospective cohort

Zhongda prospective cohort

Benign+nsPCa

csPCa

p value#

Benign+nsPCa

csPCa

p value#

Benign+nsPCa

csPCa

p value#

Benign+nsPCa

csPCa

p value#

No. pts (%)

2409 (74.6%)

821 (25.4%)

 

603 (74.6%)

205 (25.4%)

 

274 (60.9%)

176 (39.1%)

 

162 (62.5%)

97 (37.5%)

 

Age (media, IQR)

67.00 (61.00–73.00)

70.00 (64.00–76.00)

<0.001

67.00 (61.00–73.00)

72.00 (67.00–76.00)

<0.001

66.00 (61.00–71.00)

69.50 (64.00–75.00)

<0.001

69.00 (63.00–75.00)

70.00 (66.00–76.00)

0.053

PSA (media, IQR)

9.27 (6.78–12.80)

10.80 (7.73–14.51)

<0.001

9.68 (7.12–12.76)

11.64 (8.41–15.29)

<0.001

7.81 (5.91–11.29)

9.50 (6.91–12.88)

0.002

8.06 (5.97–12.06)

9.89 (7.14–12.80)

0.07

B_AREA (media, IQR)

22.79 (17.94–28.60)

17.16 (13.95–21.00)

<0.001

22.95 (17.76–29.69)

16.72 (13.76–20.67)

<0.001

23.04 (18.64–28.56)

17.15 (14.40–23.01)

<0.001

23.77 (19.46–29.68)

17.19 (14.06–20.91)

<0.001

fPSA/PSA (media, IQR)

0.16 (0.11–0.21)

0.11 (0.08–0.16)

<0.001

0.16 (0.11–0.21)

0.11 (0.08–0.15)

<0.001

0.18 (0.13–0.23)

0.13 (0.09–0.17)

<0.001

0.17 (0.13–0.21)

0.12 (0.09–0.15)

<0.001

  1. nsPCa Non-significant prostate cancer, csPCa Clinical significant prostate cancer, IQR Interquartile range, PSA Prostate-specific antigen, tPSA Total PSA, B_AREA Size of B-ultrasound cross-section prostate area
  2. # Mann-Whitney U test